Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 1 client • 12 examiners • 12 art units • 0 of 12 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Norton Rose Fulbright - UT Southwestern operates in the Biotechnology & Pharmaceuticals technology area. The firm has managed 103 career applications and currently oversees 10 pending office actions. These figures indicate the firm's historical experience and its current level of engagement with the USPTO. This data provides a baseline for understanding the firm's presence in this sector.
The firm's resolved allowance rate is 81.82. On average, the firm receives 3.44 office actions per allowance. Practitioners can use this average to estimate the frequency of examiner interactions required to reach a grant for applications in this portfolio. These metrics offer an overview of the firm's prosecution results.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (8%) |
| §103 only | 4 (33%) |
| §112 only | 1 (8%) |
| Multi-statute (no §101) | 6 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOYLAN, JAMES T | 1 | 63.2% | +10.7% |
| MUHAMMAD, KEY | 1 | 64.0% | +23.9% |
| DAUNER, JOSEPH G | 1 | 56.9% | +35.2% |
| WESTON, ALYSSA G | 1 | 59.8% | +50.9% |
| MEJIAS, SAMANTHA LEE | 1 | 46.4% | +40.9% |
| MORGAN, BAILEY MICHELLE | 1 | 56.3% | +58.3% |
| KASAYAN, KATRIEL BARCELLANO | 1 | 25.0% | +0.0% |
| HALVORSON, MARK | 1 | 47.9% | +20.7% |
| SHARIFF, MICHAEL ADAM | 1 | 80.8% | +24.7% |
| HUDSON, AMY ROSE | 1 | 74.9% | +11.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998037 | SYSTEMS AND METHODS FOR CHARACTERIZING A TUMOR MICROENVIRONMENT USING PATHOLOGICAL IMAGES | SHARIFF, MICHAEL ADAM | 46d overdue |
| 18014850 | TDP-43 BIOSENSOR CELL LINES | KASAYAN, KATRIEL BARCELLANO | 31d overdue |
| 18032760 | PROINFLAMMATORY PRODRUGS | MEJIAS, SAMANTHA LEE | 71d |
| 18697643 | OPTICAL ROTATOR SYSTEMS AND METHODS | MUHAMMAD, KEY | — |
| 18504868 | METHODS OF PREDICTING AND TREATING IMMUNOTHERAPY TOXICITY BASED ON IMMUNE CELL POPULATIONS | DAUNER, JOSEPH G | — |
| 18266712 | TAU BIOSENSOR CELL LINES | WESTON, ALYSSA G | — |
| 17905285 | METHOD FOR DIAGNOSIS AND/OR PROGNOSIS OF LIVER DISEASE PROGRESSION AND RISK OF HEPATOCELLULAR CARCINOMA AND DISCOVERY OF THERAPEUTIC COMPOUNDS AND TARGETS TO TREAT LIVER DISEASE AND CANCER | HUDSON, AMY ROSE | — |
| 17782402 | URINE ANALYSIS DEVICES AND METHODS FOR REAL TIME MONITORING OF KIDNEY FUNCTION | WESTFALL, SARAH ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998037 | SYSTEMS AND METHODS FOR CHARACTERIZING A TUMOR MICROENVIRONMENT USING PATHOLOGICAL IMAGES | SHARIFF, MICHAEL ADAM | 46d overdue |
| 18062937 | PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY | HALVORSON, MARK | 22d overdue |
| 18933931 | IMAGING SYSTEM AND METHOD TO CONVERT LATERAL SCANNING INTO AXIAL REMOTE FOCUSING | BOYLAN, JAMES T | 2d overdue |
| 18032760 | PROINFLAMMATORY PRODRUGS | MEJIAS, SAMANTHA LEE | 71d |
| 18697643 | OPTICAL ROTATOR SYSTEMS AND METHODS | MUHAMMAD, KEY | — |
| 18504868 | METHODS OF PREDICTING AND TREATING IMMUNOTHERAPY TOXICITY BASED ON IMMUNE CELL POPULATIONS | DAUNER, JOSEPH G | — |
| 18266712 | TAU BIOSENSOR CELL LINES | WESTON, ALYSSA G | — |
| 18042231 | COMBINATION IMMUNOTHERAPY METHODS FOR THE TREATMENT OF CANCER | MORGAN, BAILEY MICHELLE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| University of Texas | 12 |
| Art Unit | Apps |
|---|---|
| 2486 | 1 |
| 2872 | 1 |
| 1682 | 1 |
| 1633 | 1 |
| 1618 | 1 |
| 1645 | 1 |
| 1634 | 1 |
| 1646 | 1 |
| 2672 | 1 |
| 1636 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18933931 | IMAGING SYSTEM AND METHOD TO CONVERT LATERAL SCANNING INTO AXIAL REMOTE FOCUSING | The Board Of Regents Of The University Of Texas System | BOYLAN, JAMES T | 2486 | §103Other | Final Rejection | 2d overdue | Pending | Oct 31, 2024 |
| 18697643 | OPTICAL ROTATOR SYSTEMS AND METHODS | The Board Of Regents Of The University Of Texas System | MUHAMMAD, KEY | 2872 | §102§103§112 | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18504868 | METHODS OF PREDICTING AND TREATING IMMUNOTHERAPY TOXICITY BASED ON IMMUNE CELL POPULATIONS | The Board Of Regents Of The University Of Texas System | DAUNER, JOSEPH G | 1682 | §103§112 | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18266712 | TAU BIOSENSOR CELL LINES | The Board Of Regents Of The University Of Texas System | WESTON, ALYSSA G | 1633 | §102§103§112 | Non-Final OA | — | Pending | Jun 12, 2023 |
| 18032760 | PROINFLAMMATORY PRODRUGS | The Board Of Regents Of The University Of Texas System | MEJIAS, SAMANTHA LEE | 1618 | §102§103§112 | Non-Final OA | 71d | Pending | Apr 19, 2023 |
| 18042231 | COMBINATION IMMUNOTHERAPY METHODS FOR THE TREATMENT OF CANCER | The Board Of Regents Of The University Of Texas System | MORGAN, BAILEY MICHELLE | 1645 | §103 | Final Rejection | — | Pending | Feb 20, 2023 |
| 18014850 | TDP-43 BIOSENSOR CELL LINES | The Board Of Regents Of The University Of Texas System | KASAYAN, KATRIEL BARCELLANO | 1634 | §112 | Final Rejection | 31d overdue | Pending | Jan 06, 2023 |
| 18062937 | PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY | The Board Of Regents Of The University Of Texas System | HALVORSON, MARK | 1646 | §103Other | Final Rejection | 22d overdue | Pending | Dec 07, 2022 |
| 17998037 | SYSTEMS AND METHODS FOR CHARACTERIZING A TUMOR MICROENVIRONMENT USING PATHOLOGICAL IMAGES | The Board Of Regents Of The University Of Texas System | SHARIFF, MICHAEL ADAM | 2672 | §103§112 | Final Rejection | 46d overdue | Pending | Nov 06, 2022 |
| 17905285 | METHOD FOR DIAGNOSIS AND/OR PROGNOSIS OF LIVER DISEASE PROGRESSION AND RISK OF HEPATOCELLULAR CARCINOMA AND DISCOVERY OF THERAPEUTIC COMPOUNDS AND TARGETS TO TREAT LIVER DISEASE AND CANCER | The Board Of Regents Of The University Of Texas System | HUDSON, AMY ROSE | 1636 | §101§103§112 | Non-Final OA | — | Pending | Aug 30, 2022 |
| 17782402 | URINE ANALYSIS DEVICES AND METHODS FOR REAL TIME MONITORING OF KIDNEY FUNCTION | The Board Of Regents Of The University Of Texas System | WESTFALL, SARAH ANN | 3791 | §102§112 | Non-Final OA | — | Pending | Jun 03, 2022 |
| 17095179 | ARCHIVING RADIATION THERAPY RECORDS FOR TRANSMISSION AND REVIEW | The Board Of Regents Of The University Of Texas System | PORTER, RACHEL L | 3684 | §103 | Non-Final OA | 30d overdue | Pending | Nov 11, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial